These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 17638620

  • 1. Standard and low-dose hormone therapy for postmenopausal women--focus on the breast.
    Wang PH, Horng HC, Cheng MH, Chao HT, Chao KC.
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):127-34. PubMed ID: 17638620
    [Abstract] [Full Text] [Related]

  • 2. Benefits and risks of long-term low-dose oral continuous combined hormone therapy.
    van de Weijer PH, Mattsson LA, Ylikorkala O.
    Maturitas; 2007 Mar 20; 56(3):231-48. PubMed ID: 17034966
    [Abstract] [Full Text] [Related]

  • 3. Effects of tibolone on the breast of postmenopausal women.
    Wang PH, Cheng MH, Chao HT, Chao KC.
    Taiwan J Obstet Gynecol; 2007 Jun 20; 46(2):121-6. PubMed ID: 17638619
    [Abstract] [Full Text] [Related]

  • 4. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
    Mousa NA, Crystal P, Wolfman WL, Bedaiwy MA, Casper RF.
    Menopause; 2008 Jun 20; 15(5):875-84. PubMed ID: 18480735
    [Abstract] [Full Text] [Related]

  • 5. Prognostic features of menopausal and postmenopausal applicants for life insurance.
    Schiefeling M.
    J Insur Med; 1996 Jun 20; 28(1):27-34. PubMed ID: 10172866
    [Abstract] [Full Text] [Related]

  • 6. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials.
    Peeyananjarassri K, Baber R.
    Climacteric; 2005 Mar 20; 8(1):13-23. PubMed ID: 15804728
    [Abstract] [Full Text] [Related]

  • 7. Postmenopausal hormone therapy before and after breast cancer: clinical experiences.
    Bundred NJ, Turner LE.
    Maturitas; 2004 Sep 24; 49(1):S22-31. PubMed ID: 15351104
    [Abstract] [Full Text] [Related]

  • 8. Hormone therapy and breast cancer risk.
    Foidart JM, Desreux J, Pintiaux A, Gompel A.
    Climacteric; 2007 Oct 24; 10 Suppl 2():54-61. PubMed ID: 17882674
    [Abstract] [Full Text] [Related]

  • 9. Climacteric: concept, consequence and care.
    Taechakraichana N, Jaisamrarn U, Panyakhamlerd K, Chaikittisilpa S, Limpaphayom KK.
    J Med Assoc Thai; 2002 Jun 24; 85 Suppl 1():S1-15. PubMed ID: 12188398
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women.
    Mattsson LA, Skouby S, Rees M, Heikkinen J, Kudela M, Stadnicki-Kolendo A, Mattila L, Salminen K, Vuorela A, Mustonen M, Indivina 321 Study Group.
    Menopause Int; 2007 Sep 24; 13(3):124-31. PubMed ID: 17785038
    [Abstract] [Full Text] [Related]

  • 11. Rationale for use of lower estrogen doses for postmenopausal hormone therapy.
    Ettinger B.
    Maturitas; 2007 May 20; 57(1):81-4. PubMed ID: 17383126
    [Abstract] [Full Text] [Related]

  • 12. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S, Ylikorkala O, Arrenbrecht S.
    Int J Fertil Womens Med; 1997 May 20; 42 Suppl 2():376-87. PubMed ID: 9397385
    [Abstract] [Full Text] [Related]

  • 13. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy.
    Skouby SO, Al-Azzawi F, Barlow D, Calaf-Alsina Erdogan Ertüngealp J, Gompel A, Graziottin A, Hudita D, Pines A, Rozenberg S, Samsioe G, Stevenson JC, European Menopause and Andropause Society.
    Maturitas; 2005 May 16; 51(1):8-14. PubMed ID: 15883103
    [Abstract] [Full Text] [Related]

  • 14. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
    Soares CN, Arsenio H, Joffe H, Bankier B, Cassano P, Petrillo LF, Cohen LS.
    Menopause; 2006 May 16; 13(5):780-6. PubMed ID: 16894334
    [Abstract] [Full Text] [Related]

  • 15. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
    North American Menopause Society.
    Menopause; 2004 May 16; 11(1):11-33. PubMed ID: 14716179
    [Abstract] [Full Text] [Related]

  • 16. MF-101, an estrogen receptor beta agonist for the treatment of vasomotor symptoms in peri- and postmenopausal women.
    Stovall DW, Pinkerton JV.
    Curr Opin Investig Drugs; 2009 Apr 16; 10(4):365-71. PubMed ID: 19337958
    [Abstract] [Full Text] [Related]

  • 17. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR, Gadducci A, Gambacciani M.
    Climacteric; 2001 Sep 16; 4(3):181-93. PubMed ID: 11588941
    [Abstract] [Full Text] [Related]

  • 18. Postmenopausal hormone therapy and risk of breast cancer.
    Chen FP.
    Chang Gung Med J; 2009 Sep 16; 32(2):140-7. PubMed ID: 19403003
    [Abstract] [Full Text] [Related]

  • 19. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H.
    Climacteric; 2003 May 16; 6 Suppl 1():11-36. PubMed ID: 12945798
    [Abstract] [Full Text] [Related]

  • 20. Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.
    Col NF, Chlebowski RT.
    Menopause; 2008 May 16; 15(4 Suppl):804-9. PubMed ID: 18596602
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.